INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Unicycive Therapeutics, Inc. following a significant stock price drop after the FDA issued a Complete Response Letter for its New Drug Application [1][2]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is a company listed on NASDAQ under the ticker UNCY [1]. - The company recently faced regulatory challenges when the FDA issued a Complete Response Letter regarding its New Drug Application for OLC, intended to treat hyperphosphatemia in patients with chronic kidney disease on dialysis [2]. Group 2: Stock Performance - Following the FDA's announcement, Unicycive's stock price decreased by $2.03 per share, representing a decline of 29.85%, closing at $4.77 per share on June 30, 2025 [2]. Group 3: Legal Context - Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, is leading the investigation into Unicycive's practices, emphasizing its long history of fighting for victims of securities fraud and corporate misconduct [3].